Amarin (United States)

Recent papers from Amarin (United States)

1. Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) VariabilityEuropean Heart Journal · 2026
2. Sex differences in early study discontinuation and study drug withdrawal: insights from REDUCE-ITEuropean Heart Journal · 2026
3. Eicosapentaenoic acid (EPA) limits rapid oxidation of lipoprotein(a) [Lp(a)] yielding favorable changes in endothelial cell protein expression that may contribute to clinical benefitsEuropean Heart Journal · 2026
4. Risk-Weighted Apob Outperforms Traditional Lipid Biomarkers in Predicting Residual Cardiovascular Risk in Statin-Treated Hypertriglyceridemic Patients: Post Hoc Analysis of the Reduce-It Placebo ArmAtherosclerosis · 2026
5. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trialEuropean Heart Journal · 2024
6. Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKMAmerican Journal of Preventive Cardiology · 2025
7. Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITEuropean Journal of Preventive Cardiology · 2025
8. Eicosapentaenoic acid (EPA) limits the more rapid oxidation of lipoprotein(a) [Lp(a)] compared with other ApoB particlesCardiovascular Research · 2025
9. Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethylFrontiers in Cardiovascular Medicine · 2025
10. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized TrialJournal of the American Heart Association · 2025
11. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent EthylJournal of the American College of Cardiology · 2024
12. Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United StatesJournal of the American Heart Association · 2023
13. Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSynEuropean Heart Journal Open · 2023
14. Eicosapentaenoic acid, arachidonic acid, and triglyceride levels mediate most of the benefit of icosapent ethyl in REDUCE-ITEuropean Heart Journal · 2023
15. Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐ITJournal of the American Heart Association · 2023
16. Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statinsFrontiers in Cardiovascular Medicine · 2022
17. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smokingEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2022
18. The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent EthylAmerican Journal of Preventive Cardiology · 2022
19. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial InfarctionJournal of the American College of Cardiology · 2022
20. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCIJournal of the American Heart Association · 2022